Search

Your search keyword '"Tang, Chao-Hsiun"' showing total 555 results
Start Over Author "Tang, Chao-Hsiun"
555 results on '"Tang, Chao-Hsiun"'

10. The epidemiology, treatments and outcomes of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive early breast cancer in Taiwan.

Author

Tang, Chao-Hsiun, Newson, Rachel Sarah, Lin, Ching-Hung, Chan, Bill Hoi-Fong, Wang, Bruce CM, Shen, Shih-Pei, and Shao, Serena Yu-Ju

Abstract

Aim: Estimate patient counts, treatment patterns and outcomes of a subset of patients with early breast cancer (EBC) presenting with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive features, who are at high-risk of recurrence, in Taiwan. Materials & methods: Data from Taiwan's National Health Insurance Research Database and Taiwan Cancer Registry from 1 January 2011 to 31 December 2020 were analyzed. Results: There were 4500 patients with high-risk EBC (10.4% of all patients with EBC) from 2012 to 2018, with an annual average incidence of 643 that increased over time. Five-year progression was 24.8% in patients with high-risk EBC and 8-year survival was low (69.6%). Conclusion: Patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node positive high-risk EBC clinical features are an increasing high-risk subset of all patients with EBC. Article highlights A subset of patients with early breast cancer (EBC) (i.e., hormone receptor positive, human epidermal growth factor receptor 2 negative, stage IA–IIIC patients) presenting with node-positive characteristics and high-risk clinical features ('high-risk'), are at higher risk of recurrence. This study used Taiwan's National Health Insurance Research Database and Taiwan Cancer Registry to understand the patient population facing this higher risk in Taiwan. There were 4500 patients with high-risk EBC (10.4% of all patients with EBC) from 2012 to 2018, with an annual average incidence of 643, which increased annually. Within both the adjuvant therapy only and in combination with neoadjuvant therapy, the triple therapy combination of chemotherapy, radiotherapy and hormone therapy was the most common treatment. Within hormone therapy, tamoxifen and letrozole were the most used treatments. Five-year progression was higher in the EBC high-risk cohort compared with all patients with EBC cohort. Eight-year survival was low in patients with high-risk EBC. Novel treatments and innovations are needed to alleviate patient burden. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: A nationwide case–control study.

Author

Hsieh, Bing‐Jun, Shen, Dereck, Chan, Tom C., Cho, Yung‐Tsu, Tang, Chao‐Hsiun, and Chu, Chia‐Yu

Subjects
YOUNG adults, OSTEOPOROSIS, TAIWANESE people, HIP fractures, CASE-control method, BONE fractures, CORTICOSTEROIDS
Abstract

Background: Connections between long‐term use of topical corticosteroids (TCSs) of varying potency and osteoporosis and major osteoporotic fracture (MOF) are unclear. Susceptibility to adverse bone effects of TCSs in different sex, age and ethnic groups is unknown too. Objectives: To demonstrate the association between cumulative dose of TCSs of varying potency and osteoporosis and MOF in Taiwanese population, with stratified analysis of sex and age. Methods: We conducted a nationwide case–control study and obtained data from Taiwan National Health Insurance Research Database. Cumulative TCS doses in different exposure periods were calculated, and the potency of TCSs was converted to prednisolone equivalent. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for osteoporosis and MOF associated with TCS use. Results: From 2017 to 2020, 129,682 osteoporosis cases and 34,999 MOF cases were selected and randomly matched with 518,728 and 139,996 controls by sex and age. We found clear dose–response relationships between long‐term TCS exposure and osteoporosis and MOF. For example, compared to no TCS use, adjusted ORs of osteoporosis were 1.216 (95% CI 1.189–1.243), 1.260 (95% CI, 1.241–1.280) and 1.341 (95% CI, 1.314–1.369) for exposure to low, medium and high cumulative TCS doses, respectively, over 5 years. Adjusted ORs of MOF were 1.118 (95% CI 1.069–1.170), 1.191 (95% CI, 1.156–1.227) and 1.288 (95% CI, 1.238–1.340) for exposure to low, medium and high cumulative TCS doses, respectively, over 5 years. Stratified analysis showed women had higher ORs of osteoporosis and MOF compared to men. Younger people (<50 years) had highest OR of osteoporosis compared to other age groups. Conclusions: Higher cumulative TCS dose was associated with increased risk of osteoporosis and MOF. Long‐term use of TCSs should be cautious, especially in susceptible populations such as women and young people. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results